Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.
Saved in:
| Title: | Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice. |
|---|---|
| Authors: | Shaffer BC; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., de Lima M; Division of Hematology and Oncology, and Stem Cell Transplant Program, Case Western Reserve University, Cleveland, OH, USA., Jimenez Jimenez AM; Division of Transplantation and Cell Therapy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA. amjimenez@miami.edu. |
| Source: | Bone marrow transplantation [Bone Marrow Transplant] 2025 Feb; Vol. 60 (2), pp. 128-134. Date of Electronic Publication: 2024 Nov 20. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
